75 related articles for article (PubMed ID: 19731877)
1. [IKARUS Project--incidence of bone events in breast cancer: retrospective analysis of patients in oncological centres in the Czech Republic and Slovakia].
Fínek J; Prausová J; Cmejlová V; Cwiertka K; Svébisová H; Vyzula R; Holánek M; Bodorová M; Slavícek L; Kubecová M; Loukotková L; Neumanová R; Lepeyová K; Lysý M; Smejkal J; Soumarová R; Rysková J; Kalisová K; Machanová J; Bohusová M; Alaksa V; Stresko M; Samanová T; Kůta M; Vanásek J; Vondrácková K; Vargovcíková M; Petera J; Pritzová E; Bednarík O; Hlavácová A; Jancoková I; Szeghöová O; Dammak A; Lesková J; Chroust K; Dusek L
Klin Onkol; 2009; 22(4):154-62. PubMed ID: 19731877
[TBL] [Abstract][Full Text] [Related]
2. [Experience in data management of the clinical retrospective project in Czech and Slovak oncology centres (IKARUS Project)].
Chroust K; Fínek J; Zemánek P; Brabec P; Dusek L
Klin Onkol; 2009; 22(4):163-7. PubMed ID: 19731878
[TBL] [Abstract][Full Text] [Related]
3. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Liauw W; Segelov E; Lih A; Dunleavy R; Links M; Ward R
BMC Cancer; 2005 Jul; 5():89. PubMed ID: 16048654
[TBL] [Abstract][Full Text] [Related]
4. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate therapy for patients with breast carcinoma.
Plunkett TA; Rubens RD
Cancer; 2003 Feb; 97(3 Suppl):854-8. PubMed ID: 12548586
[TBL] [Abstract][Full Text] [Related]
7. Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer.
van Holten-Verzantvoort AT; Papapoulos SE
Medicina (B Aires); 1997; 57 Suppl 1():109-13. PubMed ID: 9567363
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
9. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
Mystakidou K; Katsouda E; Stathopoulou E; Vlahos L
Cancer Treat Rev; 2005 Jun; 31(4):303-11. PubMed ID: 16039956
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.
Weinfurt KP; Castel LD; Li Y; Timbie JW; Glendenning GA; Schulman KA
Med Care; 2004 Feb; 42(2):164-75. PubMed ID: 14734954
[TBL] [Abstract][Full Text] [Related]
11. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials in metastatic breast cancer to bone: past--present--future.
Body JJ
Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
[TBL] [Abstract][Full Text] [Related]
13. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
14. Management of bisphosphonate treatment in clinical practice.
Aapro MS
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S28-32. PubMed ID: 18068488
[TBL] [Abstract][Full Text] [Related]
15. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates and metastatic breast carcinoma.
Lipton A
Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
[TBL] [Abstract][Full Text] [Related]
19. New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.
Rosen LS
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):26-32. PubMed ID: 15202585
[TBL] [Abstract][Full Text] [Related]
20. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
